World Health Organization Raises Concern Over Critical Shortage of Weight-Loss Jabs

Under one in 10 individuals that would benefit from GLP-1 drugs such as Wegovy have access to them, warns the global health agency as it issues its inaugural recommendations on the medications.

With more than one billion people worldwide currently classified as obese, it is calling for broader and more equitable access to GLP-1 medication.

Based on forecasts, over two billion could be obese by 2030 unless action is taken.

"Our new guidelines recognises that obesity is a long-term condition that can be managed with comprehensive and lifelong support," remarked WHO director-general Tedros Adhanom Ghebreyesus.

High costs, constrained manufacturing, and supply-chain constraints are key obstacles to universal access to the injections that can assist patients in reducing considerable body mass, says the body.

GLP-1 Therapy Shortage

Even in the present most optimistic case, the production of such drugs would only suffice for approximately 100 million people – fewer than 10% of those who need them, per the WHO.

The guideline urges governments and firms to expand availability, through measures such as licensing agreements.

Exclusive production rights on the active ingredient – the main component of a leading brand – is due to expire in a number of countries in 2026.

How Obesity Drugs Function

GLP-1 drugs imitate a biological compound to slow digestion, suppress the appetite and boost the sense of being full so users reduce food intake.

Individuals usually see weight reduction within a few weeks of commencing the regular doses.

Evidence points to users may regain a significant portion a year later of stopping the drug, because their normal food cravings come back.

To be above a healthy weight increases your risk for contracting medical conditions, such as diabetes, cardiovascular issues, stroke, and certain cancers.

Excess weight concerns individuals in countries worldwide and was associated with millions of fatalities worldwide in 2024, as per the WHO.